検索結果

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

D; Minoru Kanamoto, MSc; Kazunori Omatsu, BSc AAO 2025 開催日：2025年10月17日～2025年10月20日 開催地：Orlando, FL, USA Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double-Masked, P...

Milestones in Our History | About Senju | SENJU Pharmaceutical

h Company head office and Osaka branch are relocated to Hiranomachi, Higashi-ku, Osaka 1974 June Fukusaki Plant for manufacturing established in Kanzaki-gun, Hyogo June Shoji Yoshida became the Presid...

sease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tear film causing discomfort and/or visual impairment, accompanied by ocular surface disorder” *. Recently, the ...

sease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tear film causing discomfort and/or visual impairment, accompanied by ocular surface disorder” *. Recently, the ...

ent Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition Senju Pharma...